We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current APLS market cap is 3.75B. The company's latest EPS is USD -4.2255 and P/E is -7.14.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 110.4M | 146.38M | 172.33M | 199.68M | 196.83M |
| Operating Income | -137.08M | -84.52M | -62.09M | -29.44M | -47.28M |
| Net Income | -140.24M | -85.58M | -66.42M | -37.66M | -57.45M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 250.65M | 66.56M | 75.42M | 396.59M |
| Operating Income | -288.02M | -213.73M | -536.28M | -594.61M | -517.12M |
| Net Income | -304.71M | -344.87M | -746.35M | -652.17M | -525.63M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 818.22M | 788.73M | 831.93M | 904.48M | 901.87M |
| Total Liabilities | 585.95M | 594.21M | 565.25M | 640.16M | 664.75M |
| Total Equity | 232.27M | 194.52M | 266.68M | 264.33M | 237.12M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 389.25M | 960.57M | 881.77M | 760.22M | 788.73M |
| Total Liabilities | 355.02M | 756.01M | 683.1M | 590.35M | 594.21M |
| Total Equity | 34.23M | 204.56M | 198.66M | 169.87M | 194.52M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -496.86M | -594.74M | -132.98M | -141.32M | -107.23M |
| Investing | -678k | -674k | -293k | -383k | -383k |
| Financing | 398.41M | 394.5M | 108.21M | 150.7M | 153.24M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -211.14M | -160.49M | -563.13M | -513.75M | -594.74M |
| Investing | -1.69M | -316.99M | 247.62M | 59.89M | -674k |
| Financing | 388.54M | 692.18M | 392.24M | 365.66M | 394.5M |
| Market Cap | 3.75B |
| Price to Earnings Ratio | -7.14 |
| Price to Sales Ratio | 9.46 |
| Price to Cash Ratio | 10.68 |
| Price to Book Ratio | 19.28 |
| Dividend Yield | - |
| Shares Outstanding | 124.39M |
| Average Volume (1 week) | 1.66M |
| Average Volume (1 Month) | 2.01M |
| 52 Week Change | -52.95% |
| 52 Week High | 71.90 |
| 52 Week Low | 24.34 |
| Spread (Intraday) | 0.65 (2.14%) |
| Company Name | Apellis Pharmaceuticals Inc |
| Address |
108 lakeland ave dover, delaware 19901 |
| Website | https://www.apellis.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
